Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 3/20 | 0.53 |
| ▸ | RBPJ | Q06330 | 3/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 9/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287904 | 1.00 | NOTCH1 (0.53) | NOTCH1RBPJMMEACESCN9A | |
| SCHEMBL3289472 | 0.84 | NOTCH1 (0.61) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3286164 | 0.78 | PSEN1 (0.64) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL4108341 | 0.78 | PSEN1 (0.64) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL7246830 | 0.78 | NOTCH1 (0.57) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3289624 | 0.77 | NOTCH1 (0.69) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL4485658 | 0.77 | APP (0.58) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3286623 | 0.77 | NOTCH1 (0.66) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL4490715 | 0.76 | APP (0.68) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL13875791 | 0.76 | SCN9A (0.53) | MMEACESCN9AXIAPRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | BACE1, APP, APH1B | NOTCH1 134/4885RBPJ 2432/4885MME 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.